化疗联合贝伐珠单抗治疗对晚期结肠癌的疗效及对其凝血功能的影响分析

Effect of Chemotherapy Combined with Bevacizumab in the Treatment of Advanced Colon Cancer and its Influence on Coagulation Function

目的探析化疗联合贝伐珠单抗治疗对晚期结肠癌的疗效及对其凝血功能的影响。方法选取2017年5月至2020年5月南通市通州区人民医院收治的60例晚期结肠癌患者为研究对象,以抛硬币法分为对照组与联合组,每组30例。对照组予以单纯化疗,联合组予以化疗联合贝伐珠单抗治疗,比较两组临床疗效、凝血功能、免疫功能、肿瘤标志物。结果联合组临床总有效率显著高于对照组(P<0.05)。治疗后两组凝血酶原时间(PT)、部分活化凝血酶原时间(APTT)、纤维蛋白原(FIB)、血小板计数(PLT)均较治疗前降低(P<0.05);且联合组治疗后PT、APTT、FIB、PLT较对照组更低(P<0.05)。两组治疗后血清白蛋白(ALB)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)与治疗前比较均降低(P<0.05);但两组组间比较均差异无统计学意义(P>0.05)。治疗后两组糖类抗原125(CA125)、癌胚抗原(CEA)均较治疗前降低(P<0.05);且联合组治疗后CEA、CA125较对照组更低(P<0.05)。结论晚期结肠癌患者应用化疗联合贝伐珠单抗治疗效果更显著,有助于改善患者凝血功能,且不会明显降低免疫功能。

Objective To explore the effect of chemotherapy combined with bevacizumab on advanced colon cancer and its coagulation function.Methods A total of 60 patients with advanced colon cancer admitted to People's Hospital of Tongzhou District from May 2017 to May 2020 were selected as the research objects and divided into control group and combined group by coin tossing method,with 30 cases in each group.The control group was treated with chemotherapy alone,while the combined group was treated with bevacizumab.The clinical efficacy,coagulation function,immune function and tumor markers of the two groups were compared.Results The total effective rate of the combined group was significantly higher than that of the control group(P<0.05).After treatment,prothrombin time(PT),partially activated prothrombin time(APTT),fibrinogen(FIB)and platelet count(PLT)in two groups of the two groups were lower than those before treatment(P<0.05),and PT,APTT,FIB and PLT of the combined group were lower than those of the control group(P<0.05).After treatment,the serum albumin(ALB),immunoglobulin A(IgA)and immunoglobulin G(IgG)of the two groups were lower than those before treatment(P<0.05),but there was no significant difference between the two groups(P>0.05).After treatment,carbohydrate antigen 125(CA125)and carcinoembryonic antigen(CEA)in the two groups were lower than before treatment(P<0.05),and CEA and CA125 in the combined group were lower than those in the control group(P<0.05).Conclusion Chemotherapy combined with bevacizumab is more effective in the treatment of advanced colon cancer,which helps to improve the coagulation function of patients,and does not significantly reduce the immune function.